Prescriber Survey to Assess Boxed Warnings Perceptions

Survey Questionnaire: Vulvar and Vaginal Atrophy

(Questions used for pre-testing condition are included at the end)

Introductory Script:

Thank you for your participation in this survey. The first few questions will focus on the condition of vulvar and vaginal atrophy in menopause, which you may also know as postmenopausal atrophic vaginitis.

**//PROGRAMMING NOTES: Display each question on its own separate screen. Do not allow participants to go back on any screen. Include soft prompts for all items. //**

**Question Type:** Single Punch

**Question 1**

How experienced are you with treating vulvar and vaginal atrophy?

**Variable Label**: Q1 Familiarity with treating VVA

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all experienced |
| 2 | Slightly experienced |
| 3 | Somewhat experienced |
| 4 | Experienced |
| 5 | Very experienced |
| --99 | Refused |

**Question Type:** Single Punch

**Question 2**

How many patients do you typically see for treatment of vulvar and vaginal atrophy?

**Variable Label:** Q2 Number of patients typically seen

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | One to two patients each week, or fewer |
| 2 | Several patients a week |
| 3 | Several patients a day |
| --98 | Unsure/Don’t know |
| --99 | Refused |

**Question Type:** Single Punch

**Question 3**

In general, how bothersome are symptoms of vulvar and vaginal atrophy for most of your patients who have the condition?

**Variable Label:** Q3 Bothersomeness of symptoms

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all bothersome |
| 2 | Slightly bothersome |
| 3 | Somewhat bothersome |
| 4 | Bothersome |
| 5 | Very bothersome |
| --98 | Unsure/Don’t know |
| --99 | Refused |

**Question Type:** Single Punch

**Question 4A**

Which of the following is true of your prescribing vaginal inserts (e.g., Vagifem, Imvexxy) for the treatment of vulvar and vaginal atrophy?

**Variable Label:** Q4A Experience prescribing vaginal inserts

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | I have written new prescriptions for this product |
| 2 | I have only prescribed a refill for this product |
| 3 | I have never prescribed this product |
| -98 | Unsure/don’t know |
| -99 | Refused |

**// PROGRAMMING NOTE: SKIP 4B if 4A = 2, 3, 4, or -98//**

**Question Type:** Single Punch

**Question 4B**

On average, how often do you prescribe vaginal inserts (e.g., Vagifem, Imvexxy) for the treatment of vulvar and vaginal atrophy?

**Variable Label:** Q4B Frequency of prescribing vaginal inserts

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | I prescribe this product one or more times a week |
| 2 | I prescribe this product a few times a month |
| 3 | I prescribe this product a few times a year |
| -98 | Unsure/Don’t know |
| -99 | Refused |

**Question Type:** Multi Punch

**Question 5**

Which of the following other treatments would you recommended or prescribe in a typical month? (Select all that apply.)

|  |  |  |
| --- | --- | --- |
| **Value** | **Value Label** | **Variable Label** |
| **1** | Over-the-counter products (e.g., personal lubricant) | Q5\_1 Typical treatment: OTC products |
| 2 | Vaginal estrogen rings (e.g., Estring, Femring) | Q5\_2 Typical treatment: Estrogen rings |
| 3 | Vaginal estrogen creams (e.g., Premarin, Estrace) | Q5\_3 Typical treatment: Estrogen creams |
| 4 | Topical estrogen gels (e.g., Estrogel, Divigel) | Q5\_4 Typical treatment: Estrogen gels |
| 5 | Oral estrogens (e.g., Premarin) | Q5\_5 Typical treatment: Oral estrogens |
| 6 | Estrogen transdermal patches (e.g., Alora, Estraderm) | Q5\_6 Typical treatment: Estrogen patch |
| 7 | Other prescription product that does not contain estrogen | Q5\_7 Typical treatment: Other prescription product w/o estrogen |
| 8 | Other (specify) | Q5\_8 Typical treatment: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

For the next few questions, we would like you to consider your patients who are postmenopausal women with vulvo-vaginal atrophy and are complaining of symptoms such as vaginal itching and discomfort or pain during intercourse. They have previously tried over-the-counter ointments with little success.

**// PROGRAMMING NOTE: [SHOW SCENARIO AT THE TOP OF THE SCREEN FOR QUESTION 6]//**

**Question Type:** Single Punch

**Question 6**

How likely are you to discuss vaginal inserts, such as Vagifem or Imvexxy, as a potential option for these patients?

**Variable Label**: Q6 Likelihood of discussing inserts

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Very unlikely |
| 2 | Unlikely |
| 3 | Somewhat likely |
| 4 | Likely |
| 5 | Very likely |
| -99 | Refused |

**Question Type:** Single Punch

**Question 7**

Which of the following statements describe your assessment of the safety of vaginal inserts used to treat vulvar and vaginal atrophy?

**Variable Label:** Q7 Risk assessment of vaginal inserts

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Risks are minimal for almost all patients |
| 2 | Risks are minimal for most patients, but are significant for some patients |
| 3 | Risks are significant for most patients |
| 4 | I am not familiar enough with vaginal inserts to make an assessment |
| -99 | Refused |

**Question Type:** Single Punch

**Question 8A**

Which statement best describes your assessment of the safety of vaginal inserts compared to oral estrogen products?

**Variable Label:** Q8AAssessment of inserts vs. oral estrogen

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Vaginal inserts are safer than oral estrogen products |
| 2 | Vaginal inserts are less safe than oral estrogen products |
| 3 | Vaginal inserts are no more and no less safe than oral estrogen products |
| 4 | The safety of vaginal inserts versus oral estrogen products has not been established |
| 5 | I am not familiar enough with vaginal inserts to make an assessment |
| -99 | Refused |

**Question Type:** Single Punch

**Question 8B**

Which statement best describes your assessment of the safety of vaginal inserts compared to transdermal estrogen products?

**Variable Label:**  Q8B Assessment of inserts vs. transdermal estrogen

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Vaginal inserts are safer than transdermal estrogen products |
| 2 | Vaginal inserts are less safe than transdermal estrogen products |
| 3 | Vaginal inserts are no more and no less safe than transdermal estrogen products |
| 4 | The safety of vaginal inserts versus transdermal estrogen products has not been established |
| 5 | I am not familiar enough with vaginal inserts to make an assessment |
| -99 | Refused |

**Question Type:** Single Punch

**Question 8C**

Which statement best describes your general perspective on the benefits versus risks of vaginal inserts for patients with vulvar and vaginal atrophy.

**Variable Label:** Q8C Benefits/risks of inserts

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | The benefits of vaginal inserts outweigh the risks for most patients |
| 2 | The benefits of vaginal inserts outweigh the risks for some, but not most, patients |
| 3 | The benefits of vaginal inserts outweigh the risks for very few patients |
| 4 | I am not familiar enough with vaginal inserts to make an assessment |
| -99 | Refused |

**Question Type:** Multi Punch

**Question 9**

Which of the following factors play the most important role when deciding whether or not to prescribe vaginal inserts to a patient with vulvar and vaginal atrophy? Please choose the three factors that you consider to be most important. **[//Multi-punch//]**

**//PROGRAMMING NOTE: ALLOW PARTICIPANTS TO SELECT UP TO THREE ANSWERS//**

**[RANDOM ORDER EXCEPT FOR OTHER]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q9\_1 | Considerations of this patient’s ability to use the product as prescribed | Q9\_1 Factor: Patient ability to use |
| Q9\_2 | This patient’s understanding of and comfort with the risks of this medication | Q9\_2 Factor: Understanding and comfort with risks |
| Q9\_3 | This patient’s previous experience with treatments (over-the-counter and prescription) | Q9\_3 Factor: Patient’s previous experience |
| Q9\_4 | This patient’s medical and health context (e.g., medical history, comorbidities, family history) | Q9\_4 Factor: Medical and health context |
| Q9\_5 | Considerations of this patient’s access to the product (e.g., cost, insurance) | Q9\_5 Factor: Patient access |
| Q9\_6 | Extent, duration, and severity of this patient’s symptoms | Q9\_6 Factor: Symptoms |
| Q9\_7 | Patient’s preference for a mode of administration | Q9\_7 Factor: Patient preference for administration |
| Q9\_8 | Potential duration of treatment use/course | Q9\_8 Factor: Duration |
| Q9\_9 | Other (please specify) | Q9\_9 Factor: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**Question Type:** Multi Punch

**Question 10**

What are the top three comments or questions you have you heard from patients about using vaginal inserts to treat vulvar and vaginal atrophy? (Select up to three.) **[//Multi-punch//]**

**//PROGRAMMING NOTE: ALLOW PARTICIPANTS TO SELECT UP TO THREE ANSWERS//**

**[RANDOM ORDER, EXCEPT FOR OTHER]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q10\_1 | Pros about vaginal inserts’ application method | Q10\_1 Pros application method |
| Q10\_2 | Hearing positive things about how well vaginal inserts work | Q10\_2 Heard positive things |
| Q10\_3 | Whether vaginal inserts may be safer than other estrogen treatments | Q10\_3 Inserts safer than other estrogen |
| Q10\_4 | A desire to try something new | Q10\_4 Try something new |
| Q10\_5 | Cons about vaginal inserts’ application method | Q10\_5 Cons application method |
| Q10\_6 | Concerns about insurance coverage or cost | Q10\_6 Insurance coverage/cost |
| Q10\_7 | Hearing negative things about how well vaginal inserts work | Q10\_7 Hearing negative things |
| Q10\_8 | Concerns about using an estrogen treatment | Q10\_8 General concerns re: estrogen |
| Q10\_9 | Other (specify) | Q10\_9 Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**Question Type:** Multi Punch

**Question 11**

What are the top three topics that you prioritize when talking to your patients about vaginal inserts as a treatment option?

**//PROGRAMMING NOTE: ALLOW PARTICIPANT TO SELECT UP TO THREE ANSWERS//**

**[RANDOM ORDER EXCEPT FOR LAST OPTION] [//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q11\_1 | How the product works | Q11\_1 Talking top 3: How product works |
| Q11\_2 | Expected benefits of the product | Q11\_2 Talking top 3: Expected benefits |
| Q11\_3 | Common side effects of the product | Q11\_3 Talking top 3: Common side effects |
| Q11\_4 | Rare but serious side effects of the product | Q11\_4 Talking top 3: Rare serious effects |
| Q11\_5 | Patient’s medical history (e.g., personal history or family history, possible co-morbidities) | Q11\_5 Talking top 3: Medical history |
| Q11\_6 | The importance of using the product as directed | Q11\_6 Talking top 3: Importance of use as directed |
| Q11\_7 | Other (Specify) | Q11\_7 Talking top 3: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**//PROGRAMMING NOTE: If Q11D selected, display Q11\_RISKS. OTHERWISE, PROCEED TO Q12 //**

**Question Type:** Open End Essay

**Question 11\_RISKS**

You said that you discuss rare but serious side effects of the product. What potential side effects do you discuss?

**Variable Label:**  Q11\_RISKS Side effects discussed

**Question Type:** Multi Punch

**Question 12**

How do you most commonly monitor your patients for potential safety risks and side effects after prescribing vaginal inserts for vulvar and vaginal atrophy? Select all that apply. **[//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Value** | **Variable Label** |
| Q12\_1 | I schedule routine follow-up appointments with patients. | Q12\_1 Monitor: Follow-up appointment |
| Q12\_2 | I instruct patients to get bloodwork before follow-up appointment. | Q12\_2: Monitor: Bloodwork |
| Q12\_3 | I instruct patients to call and schedule an appointment if they experience side effects. | Q12\_3 Monitor: Appointment if side effects |
| Q12\_4 | I leave it to the patient to follow up if they feel a need to. | Q12\_4 Monitor: Leave up to patient |
| Q12\_5 | A follow-up appointment is not necessary. | Q12\_5 Monitor: Follow-up not necessary |
| Q12\_6 | Other (specify) | Q12\_6 Monitor: Other |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Selected |
| 0 | Not selected |

**Question Type:** Grid

**Question 13**

How often do you look for information about vaginal inserts or other products from the following sources:

**[RANDOM ORDER]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q13\_ 1 | Medical journals | Q13\_1 Info: Medical journals |
| Q13\_2 | Medical websites or software (e.g. UpToDate, Epocrates, Medscape) | Q13\_2 Info: Medical websites or software |
| Q13\_3 | Drug company/pharmaceutical representatives or their website | Q13\_3 Info: Drug company rep or website |
| Q13\_4 | Go online/use a search engine (e.g., Google) | Q13\_4 Info: Online search |
| Q13\_5 | Professional medical societies (e.g., publications, guidelines) | Q13\_5 Info: Professional medical societies |
| Q13\_6 | Conferences | Q13\_6 Info: Conferences |
| Q13\_7 | Discussion with colleagues (e.g., in person, email) | Q13\_7 Info: Discussion w/ colleagues |
| Q13\_8 | FDA website or other FDA sources of information (e.g., email, alerts) | Q13\_8 Info: FDA |
| Q13\_9 | Other government agencies (e.g., NIH, CDC) | Q13\_9 Info: Other government agencies |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Never |
| 2 | Rarely |
| 3 | Sometimes |
| 4 | Often |

**//[SHOW QUESTION AT THE TOP OF THE SCREEN FOR QUESTION 14]//**

The next question refers to boxed warnings on the product labeling for Vagifem, a vaginal tablet, and other estrogen products.

**Question Type**: Multi-Punch

**Question 14**

In your opinion, what is the primary role of a boxed warning? *Choose up to three options.*

**//Random Order, except last three**

**//PROGRAMMING NOTE: ALLOW PARTICIPANT TO UP TO SELECT THREE ANSWERS//**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q14\_1 | To highlight the most serious potential risks of the product | Q14\_1 BW Primary Role: Highlight most serious risks |
| Q14\_2 | To provide information that should be factored into a decision to prescribe the product | Q14\_2 BW Primary Role: Provide prescribing information |
| Q14\_3 | To provide an overview of the safety profile of the product | Q14\_3 BW Primary Role: Provide safety profile overview |
| Q14\_4 | To disclose clinical trial and other product safety testing information | Q14\_4 BW Primary Role: Clinical trial and safety testing |
| Q14\_5 | To provide information that prescribers should be communicating to patients | Q14\_5 BW Primary Role: Info to communicate to patients |
| Q14\_6 | To provide information on how to safely use the product | Q14\_6 BW Primary Role: Info on how to safely use product |
| Q14\_7 | I do not see a role for them | Q14\_7 BW Primary Role: No role for BW |
| Q14\_8 | Other (specify) | Q14\_8 BW Primary Role: Other |
| Q14\_9 | Unsure/Don’t know | Q14\_9 BW Primary Role: Unsure/Don’t know |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Included |
| 0 | Not included |

**//PROGRAMMING NOTE: SHOW PARAGRAPH ON ITS OWN PAGE//**

The next set of questions will ask you more specifically about the boxed warning and prescribing information for Vagifem to treat vulvar and vaginal atrophy. This boxed warning appears on all prescription estrogen products.

**//PROGRAMMING NOTE: “NEXT” BUTTON TO PROCEED TO Q15//**

**Question Type**: Single Punch

**Question 15**

How would you rate your familiarity with the boxed warning information for Vagifem and other estrogen products?

**Variable Label:**  Q15 Familiarity with BW information for Vagifem and other estrogen products

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all familiar |
| 2 | Slightly familiar |
| 3 | Somewhat familiar |
| 4 | Familiar |
| 5 | Very familiar |
| -99 | Refused |

**Question Type**: Multi Punch

**Question 16**

Which of the following risks do you recall being included in the boxed warning for vaginal inserts? Select all that apply.

**[RANDOM ORDER EXCEPT FOR LAST TWO OPTIONS] [//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q16\_1 | Endometrial cancer | Q16\_1 Risks: Endometrial cancer |
| Q16\_2 | Endometrial hyperplasia | Q16\_2 Risks: Endometrial hyperplasia |
| Q16\_3 | Dementia | Q16\_3 Risks: Dementia |
| Q16\_4 | Stroke | Q16\_4 Risks: Stroke |
| Q16\_5 | Deep vein thrombosis (DVT) | Q16\_5 Risks: Deep vein thrombosis |
| Q16\_6 | Breast cancer | Q16\_6 Risks: Breast cancer |
| Q16\_7 | Gallbladder disease | Q16\_7 Risks: Gallbladder disease |
| Q16\_8 | Hypercalcemia | Q16\_8 Risks: Hypercalcemia |
| Q16\_9 | Visual abnormalities | Q16\_9 Risks: Visual abnormalities |
| Q16\_10 | Elevated blood pressure | Q16\_10 Risks: Elevated blood pressure |
| Q16\_11 | None of the above | Q16\_11 Risks: None of the above |
| Q16\_12 | Other (specify) | Q16\_12 Risks: Other |


|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Included |
| 2 | Not included |
| 3 | Don’t know |


**//PROGRAMMING NOTE: SHOW PARAGRAPH ON ITS OWN PAGE, THEN CLICK NEXT TO VIEW BOXED WARNING//**

We would like to show you some of the boxed warning information for Vagifem, which is available in the FDA-approved prescribing information. This boxed warning information appears on the labeling for all estrogen products. Please take a few moments to review this information.

**//PROGRAMMING NOTE: SHOW THE BOXED WARNING ON ITS OWN PAGE//**

[View boxed warning information][[1]](#footnote-1)





**//PROGRAMMING NOTE: HAVE A “NEXT” BUTTON AT THE BOTTOM OF THE BOXED WARNING PAGE TO PROCEED TO QUESTION 17//**

**Question Type:** Single Punch

**Question 17**

How useful is the information in the boxed warning for Vagifem?

**Variable Label:**  Q17 Usefulness of BW for Vagifem

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Not at all useful |
| 2 | Slightly useful |
| 3 | Somewhat useful |
| 4 | Useful |
| 5 | Very useful |
| -99 | Refused |

**Question Type:** Single Punch

**Question 18**

What is your assessment of the way the risks of Vagifem are framed in the boxed warning?

**Variable Label:**  Q18 Assessment of risk framing in Vagifem BW

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Strongly understates risk |
| 2 | Somewhat understates risk |
| 3 | Provides appropriate assessment of risk |
| 4 | Somewhat overstates risk |
| 5 | Strongly overstates risk |
| 6 | Other (specify) |
| -99 | Refused |

**Question Type:** Single Punch

**Question 19**

Which statement best reflects your opinion on the relative benefits versus risks of vaginal inserts for patients with vulvar and vaginal atrophy.

**Variable Label:**  Q19 Assessment of benefits versus risks Post-BW

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | The benefits of vaginal inserts outweigh the risks for most patients |
| 2 | The benefits of vaginal inserts outweigh the risks for some, but not most, patients |
| 3 | The benefits of vaginal inserts outweigh the risks for very few patients |
| 4 | I am not familiar enough with vaginal inserts to make an assessment |
| -99 | Refused |

**Question Type:** Multi Punch

**Question 20**

What would improve the boxed warning for Vagifem, in your opinion? (Select all that apply.) **[//Multi-punch//]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q20\_1 | Nothing, the warning is fine the way it is | Q20\_1 Improve BW: Nothing |
| Q20\_2 | Better evidence to support risk information | Q20\_2 Improve BW: Better risk info evidence |
| Q20\_3 | Decrease the amount of information given/fewer words | Q20\_3 Improve BW: Decrease amount of info/shorten |
| Q20\_4 | Simpler language | Q20\_4 Improve BW: Simpler language |
| Q20\_5 | Formatting improvements (e.g., use of boldface) | Q20\_5 Improve BW: Formatting |
| Q20\_6 | Increase the amount of information (e.g., statistics, more details) | Q20\_6 Improve BW: Increase amount of info |
| Q20\_7 | Other (Specify) | Q20\_7 Improve BW: Other (specify) |
| Q20\_8 | Unsure/Don’t know | Q20\_8 Improve BW: Unsure/Don’t know |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Included |
| 2 | Not included |

**Question Type:** Open-End Essay

**Question 21**

Please provide any specific feedback on the boxed warning information for Vagifem.

**Variable Label:**  Q21 Specific feedback on Vagifem BW information

**//PROGRAMMING NOTE: SHOW SENTENCE ON ITS OWN PAGE, THEN CLICK NEXT TO VIEW Q22//**

Please now consider boxed warnings in general, not only the one you saw for Vagifem.

**Question Type: Grid**

**Question 22**

To what degree do you agree or disagree with the following statements about boxed warnings in general (in other words, across all classes of prescription drugs)?

**[RANDOM ORDER for 1-6]**

|  |  |  |
| --- | --- | --- |
| **Variable Name** | **Variable Text** | **Variable Label** |
| Q22\_1 | Boxed warnings are very common on the products that I prescribe | Q22\_1 Agree/Disagree: BW are very common on products I prescribe |
| Q22\_2 | Boxed warnings do not generally factor heavily into my decisions on whether to prescribe a product | Q22\_2 Agree/Disagree: BW do not generally factor heavily |
| Q22\_3 | I think carefully before prescribing a product with a boxed warning if other treatments are available | Q22\_3 Agree/Disagree: I think carefully before prescribing BW product if others available |
| Q22\_4 | I counsel my patients differently when prescribing a product with a boxed warning | Q22\_4 Agree/Disagree: Counsel patients differently with BW |
| Q22\_5 | My patients rarely know whether a product would have a boxed warning or not | Q22\_5 Agree/Disagree: Patients rarely know if product has BW |
| Q22\_6 | My patients are worried or scared when they see boxed warnings | Q22\_6 Agree/Disagree: Patients worried/scared when they see BW |
| Q22\_7 | Other (specify) | Q22\_7 |

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Strongly disagree |
| 2 | Disagree |
| 3 | Neither agree nor disagree |
| 4 | Agree |
| 5 | Strongly agree |
| -98 | Unsure/Don’t know |

**Question Type:** Single Punch

**Question 23**

How favorable is your opinion of boxed warnings *in general* (across all classes of prescription drugs)?

**Variable Label:** Q23 General favorability of BW

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Very unfavorable |
| 2 | Somewhat unfavorable |
| 3 | Neither unfavorable nor favorable |
| 4 | Somewhat favorable |
| 5 | Very favorable |
| -98 | Unsure/Don’t know |
| -99 | Refused |

**Question Type**: Open End Essay

**Question 24**

In general, what suggestions do you have on how to better use boxed warnings as a tool to highlight important safety information?

**Variable Label:** Q24 Suggestions for better using BW to highlight safety info

**//DISPLAY TEXT//**

**We would like your feedback on the survey that you completed. This will help FDA improve the survey for future use with healthcare providers.**

**Question Type**: Single Punch

**Question P1**

Were you able to complete the survey in one session?

**Variable Label:** P1 One session completion

|  |  |
| --- | --- |
| **Value** | **Value Label** |
| 1 | Yes |
| 0 | No |

**Question Type**: Open End Essay

**Question P2**

Did you rely on other sources (e.g., Google, colleagues, etc.) to answer questions you found difficult to answer? If yes, please explain.

**Variable Label:** P2 Other sources

**Question Type**: Open End Essay

**Question P3**

Were there any questions you had difficulty answering? If yes, please explain.

**Variable Label:** P3 Difficulty answering question

**Question Type**: Open End Essay

**Question P4**

What other suggestions of feedback about this survey would you like to share?

**Variable Label:** P4 Other feedback

Thank you for taking this survey. Your time is greatly appreciated.

1. NIH NLM (2019). LABEL: VAGIFEM- estradiol insert. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5ad3cf6-dd96-4e64-af21-c1eee38d0b88> [↑](#footnote-ref-1)